cnbc.com / .cnbc-com-health-care / Page 3

Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.

Moderna's stock fell even though the full data, released later Thursday, appeared positive based on Wall Street expectations ahead of the release.

A new bipartisan bill aims to speed rare disease drug development by making clinical trials faster, cheaper and more accessible to patients.

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy.

FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.

Jim Cramer identified two of his favorite stocks to buy and the names he's not willing to touch just yet.

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.

Kate Ryder's Maven has AI writing all of its code and the CEO sees huge promise for the tech in women's healthcare. But there's one thing she won't cede to AI.

Walmart will offer Novo's Ozempic and Lilly's Mounjaro without charge for people with Type 2 diabetes after a new prior authorization.

UnitedHealth Group said it expects 2026 adjusted earnings of at least $20.50 per share, up from a previous outlook of $19.50 to $20.00 per share.